CRANFORD, N.J., July 26 /PRNewswire-FirstCall/ -- Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceutical company Actavis Group (ICEX: ACT), received approval from the U.S. Food & Drug Administration to market Meloxicam Tablets. Shipment of the product will begin immediately.
Meloxicam Tablets, the generic equivalent of Boehringer Ingelheim’s Mobic(R) Tablets, are available in both 7.5 mg and 15 mg strengths.
Actavis Group
Actavis, currently doing business in more than 32 countries, has become one of the largest generic pharmaceutical companies in the world. The Group has a rich history of manufacturing generic pharmaceuticals and possesses one of the largest product pipelines in the industry.
For more information, visit http://www.actavis.us.
Actavis
CONTACT: Joseph Corsetti, Actavis, +1-908-653-8121, jcorsetti@actavis.com
